Objective: This study aimed to examine the effects of adenovirus-mediated expression of p35, a baculovirus gene, on apoptosis induced by hypoxia / reoxygenation (H / R) in cardiomyocytes. Methods: Neonatal rat cardiomyocytes were infected with recombinant adenoviral vectors expressing p35 (Ad2 / CMVp35) or no transgene (Ad2 / CMVEV) and were then subjected to H / R. Separate groups of non-infected cardiomyocytes were treated with pharmacological caspase inhibitors or antioxidants. Cell viability, apoptosis, caspase activity, and cellular reactive oxygen species (ROS) were measured using various assays. Results: H / R decreased cell viability and increased cellular ROS levels, caspase activity, and cell apoptosis. Infection with Ad2 / CMVp35 effectively inhibited the increase in cellular ROS levels, the activities of caspases 3 and 8, apoptosis, and cell death following H / R, whereas Ad2 / CMVEV had no effect. Despite its ability to abolish the increase in caspase activity and partially inhibit apoptosis, the pan-caspase inhibitor ZVAD-fmk (100 mM) failed to significantly reduce cell death induced by H / R. N-acetyl-L-cysteine, an antioxidant, completely inhibited H / R-induced increase in cellular ROS levels, but reduced apoptosis and cell death by 30% only. Conclusions: Adenovirus-mediated expression of p35 effectively inhibits H / R-induced cardiomyocyte apoptosis by reducing cellular ROS levels and inhibiting caspase activity. 
. Introduction
cological caspase inhibitors such as ZVAD-fmk have been shown to protect the myocardium against ischemia / re-A family of tightly regulated caspases is the central perfusion injury [6] . Although they effectively inhibit component of a specialized cellular machinery by which caspases, their ability to inhibit disruption of the mitoapoptosis is accomplished [1] . Activation of these prochondrial membrane potential and affect the ultimate fate teases by proapoptotic stimuli results in disassembly of the of the treated cells remains controversial [7] [8] [9] [10] [11] . Such cell. Increased cardiac cell death by apoptosis has been experimental observations highlight the role of mitochonobserved in animal models of ischemia / reperfusion [2] . dria in cardiomyocyte cell death following ischemia / reCultured cardiomyocytes also undergo apoptosis, which is perfusion, consistent with the notion that inactivation of accompanied by cytochrome c release from the mitocaspases and inhibition of the apoptotic morphology does chondria and caspase activation in response to components not prevent cell death induced by some proapoptotic of ischemia / reperfusion, such as depletion of glucose and stimuli, including growth factor withdrawal, ultraviolet serum or simulated ischemia / reperfusion [3] [4] [5] . Pharmaradiation, and Bax [12] . Although the precise initiating stimuli and signaling pathways for mitochondrial damage and subsequent commitment of the cells to death following ischemia / reperfusion are not fully understood, one of the the Declaration of Helsinki (Cardiovascular Research major mechanisms is provided by oxidative stress and the 1997;35:2-3). Neonatal rat ventricular cardiomyocytes burst of reactive oxygen species (ROS) production [13, 14] .
were isolated and cultured as described previously [34] . 5 ROS can directly cause DNA strand breaks with resultant Briefly, the cells were seeded at a density of 2.0310 2 targeting of these cells for p53-mediated apoptosis through cells / cm on rat collagen type I-coated dishes and mainupregulation of Bax [15, 16] . ROS also induces the release tained in Dulbecco's modified Eagle's medium (DMEM) of cytochrome c and precursors of caspases from the supplemented with 10% (v / v) fetal bovine serum for 48 to mitochondria into the cytoplasm [17] [18] [19] [20] [21] . Antioxidants 72 h prior to use in the studies. and metallothioneins have been shown to decrease cardiac cell apoptosis following ischemia / reperfusion [22] [23] [24] [25] .
2 .3. Detection of transgene expression The baculoviral anti-apoptotic protein, p35, is a potent inhibitor of all the mammalian caspases except caspases 5
Cardiomyocytes were infected with Ad2 / CMVp35, and 9 [26] [27] [28] . Expression of p35 prevents apoptosis Ad2 / EGFP or Ad2 / CMVEV at various multiplicities of induced by various stimuli in carcinoma cells, neurons, infection (MOI) for 6 h and maintained under normal oligodendrocytes, and vascular smooth muscle cells [29- culture conditions for an additional 42 h. GFP expression 32]. Recent studies indicate that prolonged hypoxia-inwas assessed using light microscopy. For Western blot duced cell death, cytochrome c release, and caspase 3 analysis, cells were lysed and protein was separated by activation are markedly reduced in cardiomyocytes isolated sodium dodecyl sulfate-polyacrylamide gel electrophorisis from transgenic mice expressing p35, compared to car-(SDS-PAGE) and then transferred to poly(vinylidene diomyocytes from wild-type mice [33] . In this study, we difluoride) membranes. The filters were blocked with 5% investigated the effect of adenoviral-mediated gene transfer milk, followed by incubation with a rabbit anti-p35 of p35 on caspase activity, cellular ROS levels, apoptosis, monoclonal antibody (1:2000 dilution, Biocarta, San and cell viability in neonatal rat ventricular myocytes Diego, CA) and finally developed with chemiluminescence following simulated ischemia / reperfusion. We demonstra-(Amersham, Piscataway, NJ). ted that adenovirus-mediated expression of p35 effectively protected cardiomyocytes against ischemia / reperfusion 2 .4. Effects of p35 expression, caspase inhibitors and injury by reducing cellular ROS levels and by inhibiting antioxidants on cell injury induced by hypoxia / caspase activity. The ability of p35 to reduce cellular ROS reoxygenation levels and intercept ROS-initiated signaling prior to or at the mitochondrial stage of suicidal death contributes to the Cardiomyocytes were infected with Ad2 / CMVp35 (10, protection of cardiomyocytes against simulated ischemia / 100 MOI) or Ad2 / CMVEV (100 MOI) for 6 h and reperfusion injury. maintained under normal culture conditions for an additional 24 h. These cells were deprived of serum and glucose, placed in a hypoxic chamber (,1% O , 5% CO , 2 2 2 . Methods 37 8C) for 90 min, and then returned to normoxic conditions (21% O , 5% CO , 37 8C) in DMEM for an 2 2 2 .1. Construction of recombinant adenoviral vectors additional 15 h. Separate groups of non-infected cardiomyocytes were continuously treated during hypoxia / The adenoviral vectors were constructed as described reoxygenation with the non-selective pan-caspase inhibitor, previously [32] . Briefly, Ad2 / CMVp35 was an Ad2-based ZVAD-fmk (100 mM; Enzyme Systems, Livermore, CA) vector in which the E1 and E3 regions were deleted.
or the selective caspase 3 inhibitor DEVD-CHO (100 mM; Whereas the E1 region did not code any transgene, the p35 Sigma-Aldrich, St Louis, MO). ZVAD-fmk and DEVDexpression cassette driven by the human cytomegalovirus CHO are peptide (acyloxy) methylketones. N-acetyl-Lenhancer / promoter was inserted into the E3 region. The cysteine (NAC, 1 mM; Sigma-Aldrich), an antioxidant, p35 gene was cloned by PCR from baculovirus genomic was added into the culture medium of additional groups of DNA. Ad2 / EGFP encoding the green fluorescence protein non-infected cardiomyocytes 3 h before the initiation of (GFP) was also an Ad2-based vector in which the E1 hypoxia. Cell viability, caspase activity, apoptosis, and region was replaced with a GFP expression cassette driven cellular ROS levels were measured. by the human cytomegalovirus enhancer / promoter. The E4 region except ORF6 was deleted. Ad2 / CMVEV was constructed in a similar fashion as Ad2 / EGFP, except that 2 .5. Measurement of caspase activity Ad2 / CMVEV encodes no transgene.
Caspase 8 activity was measured using the ApoAlert 2 .2. Cell culture Caspase Colorimetric Assay Kit (Clontech) in cardiomyocytes harvested with 0.25% (v / v) trypsin-EDTA 4 This investigation conforms with principles outlined in h after the initiation of reoxygenation, and was then normalized to the total protein levels measured using the 2 .9. Measurement of cell viability and lactate Bradford kit from Pierce (Rockford, IL). Caspase 3 activity dehydrogenase activity was measured using the Apo-ONEீ Homogeneous Caspase-3 / 7 Assays kit (Promega, Madison, WI).
Cell viability was measured using the CellTiter96 Aqueous One kit (Promega), as outlined by the manufacturer. The cellular level of 3-
tetrazolium (MTS), an indicator of mitochondrial function of Dichlorohydrofluorescein diacetate (DCFDA; Molecular living cells, was linearly proportional to the number of Probes, Eugene, OR) was used to measure intracellular viable cardiomyocytes (r.0.98). To assess the cytoplasm ROS levels. Thirty hours following infection with Ad2 / membrane integrity, lactate dehydrogenase (LDH) activity CMVp35 or Ad2 / CMVEV (100 MOI), cardiomyocytes in in the supernatant was measured using the TOX-7 cytotox-96-well plates were incubated with DCFDA (30 mM) for icity kit (Sigma-Aldrich). 30 min and then subjected to hypoxia / reoxygenation. In separate groups of cells, NAC (1 mM) was added to the 2 .10. Statistical analysis culture medium 3 h before the initiation of hypoxia. DCFDA fluorescence levels were measured prior to hypoData are expressed as mean6S.E.M. The number of xia, or 5, 15, 30, and 60 min after the initiation of samples examined is indicated by 'n' in the figure legends. reoxygenation using a fluorimeter (Molecular Devices, Data were analyzed by ANOVA, followed by a modified Sunnyvale, CA). The excitation and emission wavelengths Student's t-test. Unpaired Student's t-test was used in were set at 488 and 530 nm, respectively. Data experiments involving two groups only. A probability (mean6S.E.M., n$3) are expressed as arbitrary units of value of less than 0.05 was considered statistically signifi-DCFDA fluorescence, or the rate of increase in DCFDA cant. fluorescence per minute over a defined period time after the initiation of reoxygenation.
. Results

.7. Measurement of the activity of antioxidant enzymes
3 .1. Adenoviral-mediated gene transfer into cardiomyocytes Total superoxide dismutase (SOD) activity was determined using the Bioxytech SOD-525 kit (OXIS Health Forty-eight hours following infection with Ad2 / Products, Portland, OR), as outlined by the manufacturer.
CMVp35 (10 and 100 MOI), cardiomyocytes expressed Copper / Zinc (Cu / Zn) SOD activity was measured in recombinant p35 protein, as measured by immunoblotting chloroform-ethanol extracted samples in which manganese (Fig. 1A) . Infection with Ad2 / EGFP at a MOI of 10, 30, (Mn) SOD was absent. Glutathione peroxidase (GPX) 100, and 300, resulted in transduction of 3363%, 7162%, activity was measured using the Bioxytech cGPx-340 kit 9561%, and 100% of neonatal rat cardiomyocytes, respec-(OXIS Health Products). The enzymatic activity was tively, as determined by light microscopy. These results normalized to the total protein levels, as measured using indicate that adenoviral vectors are capable of transducing the Bradford kit (Pierce).
cardiomyocytes efficiently. In addition, compared to timematched controls, infection with Ad2 / CMVp35 up to a MOI of 1000 did not reduce cell viability, as measured by 2 .8. Detection of apoptosis the MTS assay (Fig. 1B ).
Cardiomyocytes were fixed in 3.7% (v / v) formaldehyde.
.2. Effects of p35 on hypoxia /reoxygenation-induced Terminal deoxynucleotidyl transferase nick end-labeling
increase in caspase activity (TUNEL) was performed using the ApoTACS in situ-TACS Blue TUNEL assay kit (R&D Systems, MinHypoxia / reoxygenation increased the activities of casneapolis, MN). Nucleosome-sized DNA fragments were pases 3 and 8 in cardiomyocytes by approximately 70% labeled with streptavidin-horseradish peroxidase and then and 60%, respectively, compared to time-matched controls reacted with fluorescein-conjugated anti-streptavidin anti- (Fig. 2) . As expected, either the pan-caspase inhibitor body (Molecular Probes). The cell nuclei were counter-ZVAD-fmk or the selective caspase 3 inhibitor DEVDstained with DAPI. Apoptotic nuclei were visualized and CHO (100 mM) diminished the increase in caspase 3 photographed at 3100 magnification using a microscope activity following hypoxia / reoxygenation, but the activity with an attached video camera. The number of TUNELof caspase 8 was inhibited by the pan-caspase inhibitor positive cells was presented as a percentage of the total ZVAD-fmk only. Infection with Ad2 / CMVp35 (100 MOI) number of tropomyosin-positive cardiomyocytes.
completely inhibited the hypoxia / reoxygenation-induced increase in the activities of caspases 3 and 8, whereas levels in cardiomyocytes under control conditions, treated Ad2 / CMVEV had no effect (Fig. 2) . There was a trend with NAC (1 mM), or infected with Ad2 / CMVEV or that the antioxidant NAC also reduced caspase 3 activaAd2 / CMVp35, were 16.060.4, 10.560.1, 15.860.2, and tion, but the reduction did not reach statistical significance.
15.760.2 (arbitrary units; n$3), respectively. Due to the These results suggest that p35 inhibits activation of transfer of the cells from the hypoxic chamber to the caspases in cardiomyocytes during hypoxia / reoxygenation, DCFDA fluorescence measurement apparatus, which was as effectively as the pan-caspase inhibitor ZVAD-fmk.
set up in a normoxic environment, we could only start to reliably determine the DCFDA fluorescence levels approxi-3 .3. Effects of p35 on cellular ROS levels following mately 5 min after the initiation of reoxygenation. Fig. 3A hypoxia /reoxygenation shows that following hypoxia / reoxygenation, DCFDA fluorescence levels in non-infected cardiomyocytes were Prior to hypoxia / reoxygenation, DCFDA fluorescence significantly higher at all time-points examined, compared decreased the rate of increase in DCFDA fluorescence per minute, as effectively as NAC, whereas infection with Ad2 / CMVEV had little effect. These results suggest that, in addition to its inhibitory effect on caspase activity, p35 is also capable of reducing cellular ROS levels, as measured by DCFDA fluorescence, in cardiomyocytes following hypoxia / reoxygenation. It is likely that the ability of p35 to inhibit cellular ROS levels contributes to its effective protection of cardiomyocytes against hypoxia / reoxygenation injury.
.4. Effects of p35 on cellular SOD and GPX activity following hypoxia /reoxygenation
To assess the mechanism underlying the effect of p35 on cellular ROS levels following hypoxia / reoxygenation, we measured the activity of SOD and GPX. Infection with either Ad2 / CMVEV or Ad2 / CMVp35 did not affect the activity of Cu / Zn SOD, Mn SOD, and GPX (Fig. 4) . These results are consistent with the notion that p35 functions directly as an antioxidant by mopping up free radicals [35] .
.5. Effects of p35 on cardiomyocyte apoptosis following hypoxia /reoxygenation
The TUNEL assay was used to detect apoptotic nuclei following hypoxia / reoxygenation in cardiomyocytes. In cells maintained under normal culture conditions (control), 2% of the nuclei stained TUNEL positive (Fig. 5) . Hypoxia / reoxygenation caused no apparent cell detachment. However, the nuclei of approximately 18% of the cardiomyocytes were TUNEL positive and showed a pattern of DNA condensation and fragmentation that was characteristic of apoptosis (Fig. 5B) . Whereas Ad2 / CMVEV had no effect, the number of cardiomyocytes that (Fig. 5) . The pan-caspase CMVp35 (p35) or Ad2 / CMVEV (EV) and their non-infected counterinhibitor ZVAD-fmk (100 mM) and the antioxidant NAC parts (H / R) were subjected to hypoxia / reoxygenation. Separate groups of (1 mM) reduced TUNEL-positive cardiomyocytes to 10 non-infected cells were continuously treated with ZVAD-fmk (ZVAD, 100 mM) or DEVD-CHO (DEVD, 100 mM). NAC (1 mM) was added to and 13%, respectively, whereas selective caspase 3 inhibadditional non-infected cells 3 h prior to the initiation of hypoxia. The itor DEVD-CHO (100 mM) had no effect. Despite their cardiomyocyte apoptosis following simulated ischemia / *, **, and *** indicate P,0.01, 0.001, and 0.0001, respectively, compared to H / R or EV.
reperfusion.
to their counterparts maintained under normal culture 3 .6. Effects of p35 on hypoxia /reoxygenation-induced conditions. This increase in DCFDA fluorescence was cell death significantly inhibited by the antioxidant NAC (1 mM). Whereas Ad2 / CMVEV had no effect, infection with Ad2 / Compared to time-matched normoxic controls, hypoxia / CMVp35 significantly inhibited the increase in DCFDA reoxygenation reduced cell viability by approximately fluorescence following reoxygenation (Fig. 3A) . We also 40%, as measured by the MTS assay. Infection with analyzed the rate of increase in DCFDA fluorescence per Ad2 / CMVp35 (100 MOI) 30 h prior to hypoxia / reoxygeminute over the period from the 6th to the 15th minute and nation effectively inhibited cell death, whereas Ad2 / from the 16th to the 60th minute after the initiation of CMVEV at the same dose had no effect (Fig. 6A) . reoxygenation (Fig. 3B, C) . Infection with Ad2 / CMVp35
Although the antioxidant NAC also significantly reduced cell death, the extent of the reduction by NAC was smaller ZVAD-fmk or DEVD-CHO (Fig. 6B) . In contrast, inthan Ad2 / CMVp35. There was a trend that the panfection with Ad2 / CMVp35 significantly reduced LDH caspase inhibitor ZVAD-fmk decreased cell death, but the activity following hypoxia / reoxygenation in a dose-depenreduction did not reach statistical significance (P50.14). dent manner (Fig. 6B) . Treatment with NAC also sigTreatment with the caspase 3 selective inhibitor DEVDnificantly reduced LDH activity following hypoxia / reox-CHO had no effect. The protection of cardiomyocytes by ygenation. However, the extent of the decrease of LDH p35 was confirmed by determining the LDH activity.
activity by NAC was smaller than Ad2 / CMVp35. Taken Compared to time-matched controls, hypoxia / reoxygenatogether, adenovirus-mediated expression of p35 effectivetion increased LDH activity in the culture medium by 85%, ly inhibited cell death induced by hypoxia / reoxygenation. indicative of the disruption of the cytoplasm membrane NAC also partially inhibited cell death following hypoxia / and cell death. Infection with Ad2 / CMVEV did not reoxygenation, whereas pharmacological caspase inhibitors significantly affect LDH activity, nor did treatment with were ineffective.
. Discussion
.1. Protection of cardiomyocytes against hypoxia / reoxygenation injury by adenovirus-mediated expression of p35
The effect of p35 expression on hypoxia-induced cell injury has been assessed previously in cardiomyocytes from a transgenic mouse model. An adenoviral vector expressing the Cre-recombinase gene was used to turn on the expression of p35 prior to subjecting the cells to prolonged anaerobic conditions for 24 or 48 h in the presence of serum and glucose [33] . These authors observed that prolonged hypoxia-induced apoptosis was markedly reduced in cardiomyocytes from transgenic mice expressing p35. However, recent studies suggest that other components of ischemia / reperfusion significantly contribute to cardiomyocyte injury. Depletion of serum and glucose, an important component of ischemia, is sufficient to initiate apoptosis in cardiomyocytes [5] . Glucose uptake and glycolysis protect cardiomyocytes from hypoxia-induced apoptosis [36] . Hypoxia-induced cardiomyocyte apoptosis may require reoxygenation or a pH shift [19, 37] . In this study, we simulated ischemia / reperfusion by depleting serum and glucose and subjecting the cells to reoxygenation. We demonstrated that adenovirus-mediated gene transfer of p35 effectively protected the cardiomyocytes from simulated ischemia / reperfusion injury.
.2. Inhibition of caspase activity by p35
The ability of pharmacological caspase inhibitors to rescue cardiomyocytes from ischemia / reperfusion injury remains controversial [5] [6] [7] [8] [9] 19] . In this study, as expected, the caspase 3 selective inhibitor DEVED-CHO abolished the increased activity of caspase 3, an effector / executioner caspase, but had no effect on the elevated activity of caspase 8, an initiator caspase [1] . However, DEVED-CHO did not reduce either apoptosis, as measured by the TUNEL assay, or total cell death, as determined by the MTS and LDH assays. The pan-caspase inhibitor ZVADfmk completely inhibited hypoxia / reoxygenation induced activation of caspases 3 and 8, as did adenoviral-mediated expression of p35. However, whereas ZVAD-fmk inhibited simulated ischemia / reperfusion-induced apoptosis by 50% only, adenoviral-mediated expression of p35 reduced apoptosis by 90%. Furthermore, the inhibition of apoptotic morphology by ZVAD-fmk did not fully translate into reduction of cell death, as the decrease in total cell death by ZVAD-fmk did not reach statistical significance. These and inhibition of the apoptotic morphology does not by subtracting Cu / Zn activity from total SOD activity. The enzymatic activity was normalized to total protein levels (mean6S.E.M., n$3). prevent cell death induced by some proapoptotic stimuli Fig. 5 . Effects of p35 expression and pharmacological agents on cell apoptosis induced by hypoxia / reoxygenation. Neonatal rat cardiomyocytes infected with Ad2 / CMVp35 (p35) or Ad2 / CMVEV (EV) and their non-infected counterparts (H / R) were subjected to hypoxia / reoxygenation. Separate groups of non-infected cells were continuously treated with ZVAD-fmk (ZVAD, 100 mM) or DEVD-CHO (DEVD, 100 mM). NAC (1 mM) was added to additional non-infected cells 3 h prior to the initiation of hypoxia. Cell apoptosis was determined using the TUNEL assay. (A) shows characteristic nuclear staining of cardiomyocytes maintained under control conditions (control), subjected to hypoxia / reoxygenation (H / R), or infected with Ad2 / CMVp35 and then subjected to H / R (p35; magnification 3400). The green fluorescence depicts tropomyosin staining, while the arrow points to a TUNEL-positive nucleus. including H O , growth factor withdrawal, ultraviolet in this study, p35 expression had no effect on the activity 2 2 radiation, and Bax, which initiate mitochondria-dependent of SOD and GPX in cardiomyocytes. Although the effect apoptosis [10, 12] . The effective inhibition of caspase of p35 on catalase and other intracellular scavenging activity, apoptosis, and total cell death by adenovirussystems cannot be ruled out, these results are consistent mediated expression of p35 may imply that p35 acts at an with the notion that p35 functions directly as an antiupstream step of activation of caspases.
oxidant by mopping up free radicals [35] . NAC also reduced cardiomyocyte apoptosis and cell death following 4 .3. Inhibition of ROS production by p35 hypoxia / reoxygenation. These results suggest that the ability of p35 to reduce cellular ROS levels may contribute Cellular ROS levels are elevated following ischemia / to the protection of cardiomyocytes against hypoxia / reoxreperfusion, which contributes to reperfusion damage ygenation injury. [13, [38] [39] [40] . ROS generated by hypoxia / reoxygenation It was noted that, despite complete inhibition of the causes accumulation of ceramide, release of cytochrome c increase in cellular ROS levels, inhibition of caspase 3 and precursors of caspases from the mitochondria, and activity by NAC did not reach statistical significance. NAC apoptosis [17] [18] [19] [20] [21] 41] . ROS also directly causes DNA reduced hypoxia / reoxygenation-induced apoptosis and cell strand breaks and the cell with the damaged DNA is then death by 30% only, whereas p35 protected the vast targeted for apoptosis by p53 through upregulation of Bax majority of the cardiomyocytes subjected to hypoxia / reox- [15, 16] . Bax, a mammalian cell death protein that targets ygenation. We speculate that reduction of cellular ROS mitochondrial membranes, can induce mitochondrial damlevels and resultant interception of ROS-initiated apoptotic age and cell death even when caspases are inactivated [42] . signaling prior to or at the mitochondrial stage of suicidal Antioxidants and metallothioneins have been shown to death by p35 may account for part of the protective effect decrease cardiac cell apoptosis and total cell death followonly. In this study, caspase 8 activity was increased ing ischemia / reperfusion, highlighting the role of ROS in following hypoxia / reoxygenation. One potential mechaischemia / reperfusion injury [22] [23] [24] [25] . Recent studies sugnism for the activation of caspase 8 may involve the Fas gest that p35 reduces cellular ROS levels in S. frugiperda ligand (FasL) / Fas system [1] . Cardiac expression of both cells [35] . In this study, we demonstrated that adenovirusFasL and Fas is upregulated by ischemia / reperfusion mediated expression of p35 in cardiomyocytes effectively [3, 43, 44] . Upon binding by FasL, Fas initiates the sigreduced ROS levels following reoxygenation, as did naling cascade for recruitment and activation of caspase 8, treatment with the antioxidant NAC. Whereas the effect of an initiator caspase. Activated caspase 8 not only acts on p35 expression on the activity of catalase, the main the mitochondria but also directly activates the effector / intracellular scavenger of hydroperoxide, was not assessed executioner caspases such as caspase 3, which creates a though the relative contribution of the ability of p35 to act as an antioxidant and a caspase inhibitor to the inhibition of cell death remains unclear, both properties appear to be important for the protection of cardiomyocytes. It will be interesting to evaluate whether combining a pharmacological pan-caspase inhibitor (ZVAD-fmk) and an antioxidant (NAC) will mimic the effective protection of cardiomyocytes by p35 against hypoxia / reoxygenation injury. Further studies are also required to elucidate the role of the FasL / Fas pathway in mitochondria-dependent and -independent apoptosis following ischemia / reperfusion. In summary, we demonstrated that adenovirus-mediated expression of p35 inhibited cardiomyocyte cell death induced by simulated ischemia / reperfusion. It is likely that the effective protection of cardiomyocytes against simulated ischemia / reperfusion injury by p35 involves its ability to inhibit caspase activity and reduce cellular ROS levels. These studies may help explore the therapeutic potential of antiapoptotic proteins and compounds for the treatment of ischemic heart disease and congestive heart failure which are associated with apoptosis and loss of cardiomyocytes [2, 45] .
